We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 51

Bill Addresses Foreign Acquisitions of U.S. Food and Agricultural Businesses
  • Shook Hardy & Bacon LLP
  • USA
  • March 17 2017

The U.S. Senate is considering a bill that would give food and agriculture officials greater oversight of mergers and acquisitions involving U.S


Dietary Supplement & Cosmetics Legal Bulletin: November 2016
  • Shook Hardy & Bacon LLP
  • Canada, USA
  • November 30 2016

The Federal Trade Commission (FTC) has secured orders against 29 defendants whom it claims deceptively marketed and billed consumers for skin care


Dietary Supplement & Cosmetics Legal Bulletin: September 2016
  • Shook Hardy & Bacon LLP
  • USA
  • September 30 2016

FIRM NEWS Shook Lawyers Secure Dismissal of Two Suits Against Baby Powder Manufacturer A Superior Court of New Jersey judge has dismissed two cases


Corporate venture funding for funding surges
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

Silicon Valley Bank (SVB) has issued a report that explores health-care and biotech investments and exits based on 2013 data and concludes, "Large


Veracyte increases IPO target to $81 million
  • Shook Hardy & Bacon LLP
  • USA
  • October 31 2013

South San Francisco-based Veracyte, Inc., which earlier this year completed a $28-million Series C financing round to expand and roll out its thyroid


Biotech IPO market, booming or bubbling?
  • Shook Hardy & Bacon LLP
  • USA
  • October 17 2013

Speakers at a recent Biotechnology Industry Organization (BIO) Investor Forum in San Francisco reportedly claimed that this year's successes for


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including


Pharma and biotech stocks rise, M&A and IPO values strong, licensing deals
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Market analysts commenting on the dramatic rise in the Nasdaq Biotech Index (up 27) and the Dow Jones US Pharma Index (up 21) in the first half of


Royalty financing gains favor for VC biotech funding
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a


Biotech IPO boom continues
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen